Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intensive chemotherapy for solid tumours--current clinical applications.

S B Kaye

    Cancer Chemotherapy and Pharmacology
    |January 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Comment on: 'Metagenomic next-generation sequencing: a game changer in the diagnosis of unique intraocular infections'.

    Eye (London, England)·2026
    Same author

    Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial.

    ESMO open·2021
    Same author

    A decade of clinical development of PARP inhibitors in perspective.

    Annals of oncology : official journal of the European Society for Medical Oncology·2019
    Same author

    Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit.

    Clinical oncology (Royal College of Radiologists (Great Britain))·2017
    Same author

    The Royal College of Ophthalmologists guidelines on serum eye drops for the treatment of severe ocular surface disease: executive summary.

    Eye (London, England)·2017
    Same author

    The Royal College of Ophthalmologists guidelines on serum eye drops for the treatment of severe ocular surface disease: full report.

    Eye (London, England)·2017
    Same journal

    Off-target anti-leukemic effects of antibiotics: mechanisms and therapeutic insights.

    Cancer chemotherapy and pharmacology·2026
    Same journal

    The use of pharmacodynamic results for recommended phase II decision making in oncology clinical trials.

    Cancer chemotherapy and pharmacology·2026
    Same journal

    Composition and structure of stratum corneum intercellular lipids in patients with osimertinib-induced hand-foot syndrome.

    Cancer chemotherapy and pharmacology·2026
    Same journal

    CDK4/6 inhibitor-statin interaction and rhabdomyolysis in breast cancer treatment: a case-based systematic review.

    Cancer chemotherapy and pharmacology·2026
    Same journal

    ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.

    Cancer chemotherapy and pharmacology·2026
    Same journal

    Central nervous system penetration of imatinib in acute lymphoblastic leukemia: Pharmacokinetic analysis and clinical implications.

    Cancer chemotherapy and pharmacology·2026
    See all related articles

    High-dose chemotherapy with alkylating agents shows promise for solid tumors, especially with autologous bone marrow support. Further research is needed to optimize its role in cancer treatment.

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • High-dose chemotherapy using alkylating agents is gaining attention for solid tumor treatment.
    • Autologous bone marrow support is often used to mitigate dose-limiting myelosuppression, enabling dose escalation.

    Purpose of the Study:

    • To evaluate the efficacy and challenges of high-dose chemotherapy in treating solid tumors.
    • To explore the potential of high-dose chemotherapy as a consolidation treatment.

    Main Methods:

    • Administration of high-dose chemotherapy, as single agents or combination schedules.
    • Utilization of autologous bone marrow support to manage myelosuppression.

    Main Results:

    • Despite dose escalation possibilities, high-dose chemotherapy has not yet significantly impacted solid tumor therapy.

    Related Experiment Videos

  • New extramedullary drug toxicities have emerged at higher doses.
  • Encouraging data exists for specific tumors like small cell lung cancer, testicular cancer, ovarian cancer, and lymphoma.

    • Conclusions:

    • High-dose chemotherapy requires further investigation, particularly for drug-sensitive tumors.
    • Its role as consolidation therapy following induction treatment warrants examination.
    • Combination drug schedules may be crucial for future advancements in solid tumor control.